STAT1 contributes to HLA class I upregulation and CTL reactivity after anti-EGFR mAb cetuximab therapy in head and neck cancer patients

Detalles Bibliográficos
Autores principales: Srivastava, Raghvendra M, Jie, Hyun-bae, Ferrone, Soldano, Ferris, Robert L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Poster Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991086/
http://dx.doi.org/10.1186/2051-1426-1-S1-P175
_version_ 1782312379865890816
author Srivastava, Raghvendra M
Jie, Hyun-bae
Ferrone, Soldano
Ferris, Robert L
author_facet Srivastava, Raghvendra M
Jie, Hyun-bae
Ferrone, Soldano
Ferris, Robert L
author_sort Srivastava, Raghvendra M
collection PubMed
description
format Online
Article
Text
id pubmed-3991086
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-39910862014-05-01 STAT1 contributes to HLA class I upregulation and CTL reactivity after anti-EGFR mAb cetuximab therapy in head and neck cancer patients Srivastava, Raghvendra M Jie, Hyun-bae Ferrone, Soldano Ferris, Robert L J Immunother Cancer Poster Presentation BioMed Central 2013-11-07 /pmc/articles/PMC3991086/ http://dx.doi.org/10.1186/2051-1426-1-S1-P175 Text en Copyright © 2013 Srivastava et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Poster Presentation
Srivastava, Raghvendra M
Jie, Hyun-bae
Ferrone, Soldano
Ferris, Robert L
STAT1 contributes to HLA class I upregulation and CTL reactivity after anti-EGFR mAb cetuximab therapy in head and neck cancer patients
title STAT1 contributes to HLA class I upregulation and CTL reactivity after anti-EGFR mAb cetuximab therapy in head and neck cancer patients
title_full STAT1 contributes to HLA class I upregulation and CTL reactivity after anti-EGFR mAb cetuximab therapy in head and neck cancer patients
title_fullStr STAT1 contributes to HLA class I upregulation and CTL reactivity after anti-EGFR mAb cetuximab therapy in head and neck cancer patients
title_full_unstemmed STAT1 contributes to HLA class I upregulation and CTL reactivity after anti-EGFR mAb cetuximab therapy in head and neck cancer patients
title_short STAT1 contributes to HLA class I upregulation and CTL reactivity after anti-EGFR mAb cetuximab therapy in head and neck cancer patients
title_sort stat1 contributes to hla class i upregulation and ctl reactivity after anti-egfr mab cetuximab therapy in head and neck cancer patients
topic Poster Presentation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991086/
http://dx.doi.org/10.1186/2051-1426-1-S1-P175
work_keys_str_mv AT srivastavaraghvendram stat1contributestohlaclassiupregulationandctlreactivityafterantiegfrmabcetuximabtherapyinheadandneckcancerpatients
AT jiehyunbae stat1contributestohlaclassiupregulationandctlreactivityafterantiegfrmabcetuximabtherapyinheadandneckcancerpatients
AT ferronesoldano stat1contributestohlaclassiupregulationandctlreactivityafterantiegfrmabcetuximabtherapyinheadandneckcancerpatients
AT ferrisrobertl stat1contributestohlaclassiupregulationandctlreactivityafterantiegfrmabcetuximabtherapyinheadandneckcancerpatients

Ejemplares similares